A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, showed improvements in proptosis, clinical activity scores, and diplopia for chronic thyroid eye disease. The trial involved 188 patients, with those receiving veligrotug showing a higher proptosis responder rate, mean reduction in proptosis, and diplopia response compared to the placebo group. Veligrotug was well tolerated, with the majority of adverse events being mild. Viridian plans to submit a biologics license application for veligrotug in 2025. Overall, the study indicated positive outcomes for the treatment of chronic thyroid eye disease with veligrotug.
Source link
All endpoints achieved in phase 3 trial of chronic thyroid eye disease treatment
